165例单抗类抗肿瘤药物不良反应报告分析  

165 cases of monoclonal antibody antineoplastic adverse drug reactions report analysis

作　　者：王娟[1] 崔琪[1] 吴慧珍[1] 闫素英[1] 

机构地区：[1]首都医科大学宣武医院药剂科,北京100053

出　　处：《中国临床药理学杂志》2015年第13期1296-1298,共3页The Chinese Journal of Clinical Pharmacology

摘　　要：目的分析单抗类抗肿瘤药物不良反应发生的特点和一般规律。方法收集我院2006年1月到2012年8月上报北京市药品不良反应中心关于使用的单抗类抗肿瘤药物引起的165例不良反应,从性别、年龄、药品种类、临床转归以及不良反应在7种单抗药物中的分布和不良反应的临床表现进行分析。结果在165例不良反应患者中,男性多于女性,以50~80岁的中老年人发生率居高。不良反应的临床表现以全身性反应最为常见,其次为血液系统、皮肤及其附件损害。在转归方面,痊愈和好转占88.48%。利妥昔单抗发生一般不良反应比例最多,严重不良反应比例最高的为西妥昔单抗。结论单抗类抗肿瘤药物已广泛应用于临床,其不良反应也较为常见,应给予足够的重视,加强合理用药监护,确保患者用药安全。Objective To analysis of the monoclonal antibody anticancer drugs the characteristics of adverse drug reactions（ADR） and related factors,and provide reference for clinical rational drug use.Methods A total of 165 ADR monoclonal antibody cases drugs collected from January 2006 to August 2012 in Beijing adverse drug reaction center to statistical and analyses.Results In the 165 ADR reports,males were more than females,elderly in 50 to 80 years people were the main population of ADR.The clinical manifestations of the ADR in systemic reactions were the most common,followed by blood system damage,skin and accessories.The recovery and improvement were accounted for88.48%.Resistance in the analysis of the monoclonal antibody drug ADR report.The rituxan accounts for most general adverse drug reactions,the most serious adverse drug reaction ratio of cetuximab.Conclusion Monoclonal antibody anticancer drugs such as ADR and way to patients’gender,age,drug delivery,drug dosage form.

关 键 词：单克隆抗体 抗肿瘤药物 不良反应 

分 类 号：R979.1[医药卫生—药品] R969.3[医药卫生—药学]